Risk factor
Meaningful price volatility
Profitability factor
Very weak growth
About
Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of 4142.TW is 23 and suggests 28% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell